AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.
Metastatic Pancreatic Ductal Adenocarcinoma
DRUG: AK112, Cadonilimab, nab-paclitaxel, gemcitabine|DRUG: AK112, Cadonilimab, nab-paclitaxel, gemcitabine|DRUG: AK112, Cadonilimab, nab-paclitaxel, gemcitabine|DRUG: AK112, nab-paclitaxel, gemcitabine|DRUG: nab-paclitaxel, gemcitabine
Frequency of adverse events (AEs) and serious adverse events (SAEs), Frequency of AEs and SAEs for all Arms in phase Ib., 28days+28days|Overall Response Rate (ORR), ORR is the proportion of subjects with complete response(CR) or partial response(PR) , based on RECIST v1.1., Up to approximately 2 years
Pharmacokinetics (PK), PK parameters: serum concentrations of AK112 and Cadonilimab at different point of time, Up to Cycle 12|Anti-Drug Antibodies(ADAs), Number and percentage of patients with detectable anti-drug antibodies, Up to approximately 2 years|Progression-Free Survival (PFS), Evaluation of PFS based on RECIST v1.1., Up to approximately 2 years|Overall survival (OS), Evaluation of OS based on RECIST v1.1., Up to approximately 2 years|Disease control rate (DCR), Evaluation of DCR based on RECIST v1.1., Up to approximately 2 years|Duration of Response (DoR), Evaluation of DoR based on RECIST v1.1., Up to approximately 2 years|Time to Response (TTR), Evaluation of TTR based on RECIST v1.1., Up to approximately 2 years
This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.